Portfolio Company
GATC Health
AI driven drug discovery and precision medicine, built with a discipline first approach to validation, clarity, and real world impact.
Proven AI that transforms drug development and disease prediction
How It Works
Built on advanced artificial intelligence technologies, MAT accurately simulates systems biology to expedite drug development and optimize treatments.
GATC’s Multiomics Advanced Technology (MAT) platform is the future of drug discovery and development. It can analyze 40 trillion data points in less than 8 minutes.
Overview
Problem
- Developing medicines is extremely risky, expensive and time consuming.
- AI’s impact in drug discovery has not met market expectations.
Differentiation
- MAT simulates human physiology for rapid and more accurate novel target identification, drug discovery, and drug development.
- Disease target(s) → de risked drug candidates in months (vs years), saving hundreds of millions of dollars, and increasing likelihood of success.
- Predictive health data analysis for providers, payers, health plans, etc., the de identified data enhances GATC's drug discovery platform capabilities.
Experienced Team
John Stroh
Chief Executive Officer
- 30+ years in investment banking, specializing in health care
- Served in various C level roles with biotech companies
- Tellson Corporate Services, Managing Director Healthcare
Jayson Uffens
Chief Technology Officer/Co founder
- IrisMind, Founder & CEO
- GrubHub, Engineering VP
- Seemless, Head of Engineering
- Northrop Grumman Information Systems, Engineering Manager & Architect
Jeff Moses
President
- PowerOne Energy Corp, Co founder, CMO, Director
- Multiple C level positions with growth stage companies
- Founder & creative of ad agency serving Fortune 500 clients
Ian Jenkins
Chief Science Officer/Co founder
- Systemic Formulas, Marketing & Product Development
- Next Supplements, Dietary Supplement Designer
- Human Genome Project, Researcher
Tyrone Lam
Chief Operating Officer
- First Americans Wellness, Co founder & CEO
- OneRecovery/OneHealth (purchase by Viveraw/SimplyWell), Co founder
- NTN Buzztime (publicly traded), President & COO
- Predilytics (purchased by Welltok), VP Business Development
Vaishnavi Narayan
Product Manager
- IBM/IBM Watson, Associate Manager
- Frelii, Sr Machine Learning Engineer for deep learning models for drug activity prediction
- Brigham Young University, Graduate Research Assistant, Deep Learning for Healthcare
Eric J. Mathur
Chief Innovation Officer
- TLIT Holdings, Yulex Corporation, Synthetic Genomics, Diversa Corporation
- Internationally recognized expert in genome sciences, molecular biology, microbiology
- Named inventor on >150 patents, 50+ peer reviewed publications with >8,000 citations
Gene O’Bryan
Chief Operating Officer
- 30+ years C Level Banking & Financial Service Executive with a focus on Strategic Planning, Business Development, & Operation Management
- COO for NYSE bank holding company, lead $60M IPO to $1.8B valuation
- President/COO of PE backed regional lender that grew to a top 30 national lending institution with a $750M valuation
Jonathan Lakey, PhD, MSM
Chair of Scientific Advisory Board
- Professor Emeritus, Surgery & Biomedical Engineering, UC Irvine School of Medicine
- Adjunct Professor, WVU Medicine
- Diabetes and islet transplantation expert, Edmonton Protocol co developer
- International Speaker on islet transplantation, stem cell research and diabetes
- 500+ authored scientific papers
Waldemar Lernhardt, PhD
Vice President Scientific Operations
- ProSci, Inc., Chief Operating Officer
- ReadiX GmbH, Chief Science Officer
- Proveri Inc., President/CEO
Robert Tinder, PhD
Head of Chemical Research
- Intense Process Technologies, Lead Scientist and Chief Executive
- Sentinel Process Systems, Technical Lead: Flow Chemistry/Continuous Manufacturer
- Roche, Phizer, Ionis Pharmaceuticals, various positions
Renowned Active Advisory Team
Herbert Boyer
Scientist Advisor
- Co founder Genetech (first biotech company to go public)
- Co discovered methods that founded genetic engineering
- Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medical of Technology, National Medal of Science
Jonathan Lakey, PhDm
Chair of Scientific Advisory Board
- Professor Emeritus, Surgery & Biomedical Engineering, UC Irvine School of Medicine
- Diabetes and islet transplantation expert and co developer of the Edmonton Protocol
- International Speaker on islet transplantation, stem cell research and diabetes
- 500+ authored scientific papers
Tomas Philipson, PhD
Health Policy and Pharma Advisor
- Former Acting Chairman of the Council of Economic Advisers in the Trump administration
- Former senior economic advisor to the head of the Food and Drug Association
- Former senior economic advisor to the head of the Centers for Medicare & Medicaid Services
- Professor of Public Policy Studies Emeritus at the Univ of Chicago Harris School of Public Policy
Richard Schatz, MD
Chair of Medical Advisor Board
- Co inventor of the coronary stent and international expert in interventional cardiology
- Inducted into the National Academy of Inventors and won the prestigious Russ Prize for Bioengineering, considered the American Nobel Prize
- Adjunct Professor of Medicine and Cardiology at Duke University
Seema Gutpa, MD
Medical Advisor
- Primary Care Physician with Veterans Administration (20 years)
- Expert in Internal Medicine, Preventive Medicine, Public Health, Global Health
- Editorial Board of Internal Medicine Alerts (leading publication for medical providers)
Patrick Lilley
Science Advisor
- CEO and Founder, Liquid Biosciences, inventor 75+ patents and trade secrets
- MDEpiNet Blockchain & AI Task Force and co chair AI submcommittee
- Board Member, Mamogen, HepGene, LiquidLung
Jack Lewin, MD
Medical Advisor
- Administrator, Hawaii State Health Planning Development, Sr Advisor to Governor
- Former CEO, American College of Cardiology, California Medical Assoc
- Former President & CEO of Cardiovascular Research Foundation
Lin Yu, PhD
Board of Directors
- Former Managing Director Oppenheimer Healthcare Investment Banking
- Former Managing Director at BTIG Healthcare Investment Banking
- Ph.D. from Columbia University in chemical engineering focused on next generation DNA sequencing technologies
Jayson Hymes, MD MPH FACPM FASAM QME
Medical Advisor
- Fellow of the American College of Pain Medicine, Fellow of the American Society of Addiction Medicine, Assistant Clinical Professor Anesthesiology
- Pain Medicine at USC School of Medicine
- Former advisor to Office of National Drug Control Policy, the Medical Board of California, California Narcotics Officers Association, Los Angeles Field Division of the DEA.
Joseph Stauffer, DO, MBA, FAPCR
Medical Advisor
- CEO/Founder Alta Life Sciences, CMO Antibe Therapeutics, Chairman BioFuse Medical Technology
- Former Assistant Professor Johns Hopkins Medicine, FDA Medical Officer, Global Medical Director Abbott Labs, U.S. Navy Medical Officer; raised $650M of new equity and/or deal regulated finances
- Lectured globally on clinical drug/device research, medical affairs and the FDA regulatory protocols
Stanley Lewis, MD, MPH
Medical Advisor
- Co founder & CEO, A28 Therapeutics
- Former Chief Medical Officer, Ansun Biopharma
- Former Chief Medical Officer, TaliMed Biologics
Chad Beyer, PhD, MBA
Science Advisor
- 25 years of CNS drug discovery and development experience
- 33 INDs; 70+ manuscripts; 2 blockbuster medications
- NIDA; Wyeth; Ariel and Promentis Pharmaceuticals
Kevin Harrington
Business and Marketing Advisor
- Inventor of the Infomercial
- Shark on Shark Tank
- Serial entrepreneur for 50+ years with $6 billion in sales
Mark Palaima
Technology Advisor
- eBay, Chief Architect, Fellow, 10 years
- Inkiru, Inc (Acquired by Walmart Labs), Chief Scientist, Founder
- Ismintis Systems, Founder
Problem: Developing Medicine is Risky, Expensive
Problem: Developing Medicine is Risky, Expensive
Platform: Drug Discovery Blind Challenge
Validation Results: 11x optimization over current standards.
In a double blinded study, GATC Health's MAT AI platform was able to identify drugs that were successful in clinical trials with 88% accuracy.
Just as importantly, the platform identified drugs which failed in clinical trials at a rate of 84%.
Detailed report available upon request.
Drug Discovery is Inefficient, Expensive, and Slow
Only 40 to 50 new drugs are approved by the FDA each year.
Risky
Drug development is inherently risky with a >90% failure rate for preclinical / Phase 1 programs.
Costly
The average R&D costs for each FDA approved drug is $2.6B with $200B spent on drug development in 2020.
Slow
The average time for taking a new drug from candidate selection to launch is about 12 years.
GATC's Health Advanced AI Solution
Creating Safer and more effective therapeutics in less time, with less cost.
Greater Success
Greater than 80% success/failure prediction vs a 90% failure rate.
Less Costs
Less than $2M costs for pre clinical vs $318M and less investment lost on unsuccessful drugs.
Rapid Discovery
10 to 18 months to get through pre clinical vs 3 to 6 years also means more years of revenue while under patent.
Comparing GATC's Results to Industry Averages
Based on recent pharma industry deals, the potential value of each drug candidate is up to $350 million.
Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion (Bloomberg, Jan 6, 2022)
GATC reduces time, costs and risks before beginning human clinical trials.
GATC's Research & Pre clinical Pipeline
- In just 18 months, GATC discovered novel compounds to treat 5 diseases.
- 18 drug discovery projects in pipeline.*
- GATC’s MAT AI platform is disease agnostic, so any disease target can be addressed.
- In silico design, development and validation completed in corresponding year.
*Details on individual assets available under confidentiality agreement
Patents Filed Across Technology and Science
18 applications in process for Technology, Novel Drugs and Diagnostics.
SAMPLE OF PATENTS FILED:
- METHODS OF TREATING ADDICTION
- METHODS OF TREATING PTSD
- PRODRUGS FOR CANCER TREATMENT
- BIOMARKERS FOR EARLY DETECTION OF DIABETES
- PERSONAL WELLNESS RECOMMENDATION ENGINE
- PERSONAL WELLNESS RECOMMENDATION ENGINE FOR GENERATING A PREDICTIVE IMMUNE RESPONSE RECOMMENDATION
- PERSONAL WELLNESS RECOMMENDATION ENGINE FOR PSILOCYBIN BASED TREATMENT
- PERSONAL WELLNESS RECOMMENDATION ENGINE FOR MENTAL DEPRESSIVE ORDERS